Literature DB >> 7969403

A new class of retinoids with selective inhibition of AP-1 inhibits proliferation.

A Fanjul1, M I Dawson, P D Hobbs, L Jong, J F Cameron, E Harlev, G Graupner, X P Lu, M Pfahl.   

Abstract

Retinoids regulate many biological processes, including differentiation, morphogenesis and cell proliferation. They are also important therapeutic agents, but their clinical usefulness is limited because of side effects. Retinoid activities are mediated by specific nuclear receptors, the RARs and RXRs, which can induce transcriptional activation through specific DNA sites or by inhibiting the transcription factor AP-1 (refs 12-15), which usually mediates cell proliferation signals. Because the two types of receptor actions are mechanistically distinct, we investigated whether conformationally restricted retinoids, selective for each type of receptor action, could be identified. Here we describe a new class of retinoids that selectively inhibits AP-1 activity but does not activate transcription. These retinoids do not induce differentiation in F9 cells but inhibit effectively the proliferation of several tumour cell lines, and could thus serve as candidates for new retinoid therapeutic agents with reduced side effects.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7969403     DOI: 10.1038/372107a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  63 in total

1.  Mass-spectrometric analysis of agonist-induced retinoic acid receptor gamma conformational change.

Authors:  Valerie J Peterson; Elisabeth Barofsky; Max L Deinzer; Marcia I Dawson; Kai-Chia Feng; Xiao-kun Zhang; Machender R Madduru; Mark Leid
Journal:  Biochem J       Date:  2002-02-15       Impact factor: 3.857

Review 2.  Retinoid pathway and cancer therapeutics.

Authors:  Nathan Bushue; Yu-Jui Yvonne Wan
Journal:  Adv Drug Deliv Rev       Date:  2010-08-03       Impact factor: 15.470

3.  Nonsurgical innovations in the treatment of nonmelanoma skin cancer.

Authors:  Sadegh Amini; Martha H Viera; Whitney Valins; Brian Berman
Journal:  J Clin Aesthet Dermatol       Date:  2010-06

Review 4.  Chemoprevention of breast cancer with fenretinide.

Authors:  R Torrisi; A Decensi; F Formelli; T Camerini; G De Palo
Journal:  Drugs       Date:  2001       Impact factor: 9.546

5.  Decline in arylsulfatase B expression increases EGFR expression by inhibiting the protein-tyrosine phosphatase SHP2 and activating JNK in prostate cells.

Authors:  Sumit Bhattacharyya; Leo Feferman; Xiaorui Han; Yilan Ouyang; Fuming Zhang; Robert J Linhardt; Joanne K Tobacman
Journal:  J Biol Chem       Date:  2018-05-24       Impact factor: 5.157

6.  RNA stability regulates human T cell leukemia virus type 1 gene expression in chronically-infected CD4 T cells.

Authors:  Hsin-Ching Lin; Peter J Simon; Riza M Ysla; Steven L Zeichner; Gary Brewer; Arnold B Rabson
Journal:  Virology       Date:  2017-05-04       Impact factor: 3.616

7.  Angiotensin II regulates brain (pro)renin receptor expression through activation of cAMP response element-binding protein.

Authors:  Wencheng Li; Jiao Liu; Sean L Hammond; Ronald B Tjalkens; Zubaida Saifudeen; Yumei Feng
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2015-05-20       Impact factor: 3.619

8.  The promoter context is a decisive factor in establishing selective responsiveness to nuclear class II receptors.

Authors:  M V Sanguedolce; B P Leblanc; J L Betz; H G Stunnenberg
Journal:  EMBO J       Date:  1997-05-15       Impact factor: 11.598

9.  Retinoid antagonism of NF-IL6: insight into the mechanism of antiproliferative effects of retinoids in Kaposi's sarcoma.

Authors:  S Nagpal; J Cai; T Zheng; S Patel; R Masood; G Y Lin; S Friant; A Johnson; D L Smith; R A Chandraratna; P S Gill
Journal:  Mol Cell Biol       Date:  1997-07       Impact factor: 4.272

10.  Retinoic acid prevents experimental Cushing syndrome.

Authors:  M Páez-Pereda; D Kovalovsky; U Hopfner; M Theodoropoulou; U Pagotto; E Uhl; M Losa; J Stalla; Y Grübler; C Missale; E Arzt; G K Stalla
Journal:  J Clin Invest       Date:  2001-10       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.